Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Banner Pharmacaps petitions

This article was originally published in The Tan Sheet

Executive Summary

Softgel manufacturer requests FDA permit ANDA filing for loperamide hydrochloride 2 mg soft gelatin capsules, which have "the same active ingredient, [are] of the same strength and [are] expected to have the same therapeutic effect" as McNeil's Imodium A-D tablets but differ in dosage form. In an 1Aug. 5 citizen petition, Banner requests permission "to make an alternate dosage form available for those who have difficulty swallowing tablets or simply prefer the alternative." Generic softgel would be limited to consumers 12 and older, while Imodium tablets target children over six, but would otherwise carry identical labeling. In separate 2Aug. 8 petition, Banner requests FDA amend the OTC laxatives monograph "to state that docusate calcium...is an interchangeable ingredient with docusate sodium...in proposed monograph combinations," noting the different salts of docusate are considered identical...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094469

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel